Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials: A Review
Cyclin dependent kinase 2 (CDK2) is responsible for enforcing progression through the G1-S phase transition. Mutations and alterations in the CDK2 signaling pathway are associated with various cancers, most commonly breast, ovarian, prostate, leukemia, and lymphoma. CDK2 inhibitors have shown promis...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Innovative Healthcare Institute
2025-01-01
|
| Reeks: | Journal of Immunotherapy and Precision Oncology |
| Onderwerpen: | |
| Online toegang: | https://jipo.org/doi/pdf/10.36401/JIPO-24-22 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|